Ticker News
$AEMD News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Study finds mannose-rich extracellular vesicles elevated in Long COVID and captured by Hemopurifier's GNA resin
Aethlon announced a peer‑reviewed study showing Long COVID patients had ~2x higher levels of mannosylated extracellular vesicles (EVs) versus recovered individuals and that those mannose‑positive EVs can be bound by Galanthus nivalis agglutinin (GNA) affinity resin—the active capture component of the Hemopurifier. The study (using plasma from UCSF's LIINC cohort) also showed GNA resin reduced seven circulating microRNAs linked to immune/inflammatory pathways, providing translational rationale to test whether Hemopurifier removal of disease‑associated EVs could be a therapeutic approach, though no clinical benefit has yet been demonstrated and the company remains focused on its oncology trial.
Aethlon enters Cohort 3 of Australian Hemopurifier oncology study; posts FY2026 results
Aethlon (AEMD) advanced its Australian Hemopurifier oncology study into the third and final dosing cohort, treated the first Cohort 3 participant with three Hemopurifier sessions without device deficiencies, and reported an independent DSMB found no safety concerns after Cohort 2. The company also expanded Hemopurifier IP (U.S./EU patents for COVID/Long COVID), continued preclinical EV work in RA and CKD, and reported FY2026 results: ~$5.0M cash at year-end (plus ~$1.85M raised post-period), operating expenses down 21.9% to ~$7.3M, and a net loss of ~$7.2M.